Allergan Aesthetics Reports Trial Results
Allergan Aesthetics announced findings from two Phase 4 studies evaluating aesthetic facial treatments in adults taking glucagon-like peptide-1 medications.
The data were presented at the American Society for Dermatologic Surgery Annual Meeting held from November 5 to November 8, 2026, in San Diego. The company shared results from the HARMONY IN DIVERSITY and HALO trials, focusing on patients experiencing volume loss and skin changes from medical weight loss.
HARMONY IN DIVERSITY Trial Data
The HARMONY IN DIVERSITY study evaluated a combination of hyaluronic acid injectables, onabotulinumtoxinA, and a skincare regimen in 30 adults using GLP-1 medications. Participants showed a 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance scores 30 days after receiving onabotulinumtoxinA treatment. Most treatment-related adverse events were mild and resolved without intervention.
In a separate cohort of 100 participants aged 22 to 65 across Fitzpatrick skin types I through VI, multimodal facial and neck treatments produced a statistically significant mean improvement in satisfaction with facial appearance. Joely Kaufman-Janette, a board-certified dermatologist at the Skin Research Institute and study investigator, stated that data specific to this population provide a clearer starting point for establishing expectations and building personalized treatment plans.
Patients on GLP-1 medications are navigating real changes in how their face looks, and those changes can affect their self-image and how they engage with others,
Kaufman-Janette noted, adding, Having data specific to this population gives us a clearer starting point for setting expectations and building a treatment plan that reflects what they’re experiencing.
HALO Interim Findings
Interim results from the HALO study tracked 25 adults treated with hyaluronic acid injectables across the face. Participants registered a 39.6-point mean improvement in FACE-Q Satisfaction With Facial Appearance scores by month three. 95.7% of participants reported satisfaction with looking like themselves, while 82.6% expressed satisfaction with maintaining a natural appearance.
$ABBV Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications – In HARMONY IN DIVERSITY's 30-person medical weight loss cohort, combined hyaluronic acid injectables,…
Darin Messina, senior vice president and head of aesthetics research and development at AbbVie, noted that patient aesthetic concerns evolve over time during weight management and often require combined treatment approaches. The company also presented additional studies evaluating a growth factor serum used in a regimen with in-office procedures, and treatment sequence combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.
Frequently Asked Questions
What specific validated questionnaires were used in these Phase 4 studies?
Both studies utilized validated patient questionnaires, including FACE-Q and SKIN-Q.
How many participants were enrolled across the complete HALO study?
The interim analysis covered 25 individuals out of a total planned cohort of 75 participants.
Keep reading